Biology Reference
In-Depth Information
[6] Chu YW, Gress RE. Murine models of chronic graft-versus-host disease: insights and
unresolved issues. Biol Blood Marrow Transplant 2008;14:365-78.
[7] Matsuoka K, Kim HT, McDonough S, Bascug G, Warshauer B, Koreth J, et al. Altered
regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic
hematopoietic stem cell transplantation. J Clin Invest 2010;120:1479-93.
[8] Sarantopoulos S, Stevenson KE, Kim HT, Cutler CS, Bhuiya NS, Schowalter M, et al. Al-
tered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease.
Blood 2009;113:3865-74.
[9] Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea 3rd EP, et al. Interleukin-2
and regulatory T cells in graft-versus-host disease. N Engl J Med 2011;365:2055-66.
[10] Choi SW, Levine JE, Ferrara JL. Pathogenesis and management of graft-versus-host
disease. Immunol Allergy Clin North Am 2010;30:75-101.
[11] Ferrara JL, Abhyankar S, Gilliland DG. Cytokine storm of graft-versus-host disease: a
critical effector role for interleukin-1. Transplant Proc 1993;25:1216-7.
[12] Chen YB, Kim HT, McDonough S, Odze RD, Yao X, Lazo-Kallanian S, et al. Up-regulation
of alpha4beta7 integrin on peripheral T cell subsets correlates with the development
of acute intestinal graft-versus-host disease following allogeneic stem cell transplanta-
tion. Biol Blood Marrow Transplant 2009;15:1066-76.
[13] Przepiorka D, Anderlini P, Saliba R, Cleary K, Mehra R, Khouri I, et al. Chronic
graft-versus-host disease after allogeneic blood stem cell transplantation. Blood
2001;98:1695-700.
[14] Zhang C, Todorov I, Zhang Z, Liu Y, Kandeel F, Forman S, et al. Donor CD4+ T and B
cells in transplants induce chronic graft-versus-host disease with autoimmune mani-
festations. Blood 2006;107:2993-3001.
[15] Via CS, Shearer GM. T-cell interactions in autoimmunity: insights from a murine model
of graft-versus-host disease. Immunol Today 1988;9:207-13.
[16] Gleichmann E, Van Elven EH, Van der Veen JP. A systemic lupus erythematosus (SLE)-
like disease in mice induced by abnormal T-B cell cooperation: preferential formation
of autoantibodies characteristic of SLE. Eur J Immunol 1982;12:152-9.
[17] Fast LD. Identification of a single non-H-2 gene regulating graft-versus-host disease
response. J Immunol 1990;144:4177-82.
[18] van Rappard-van der Veen FM, Rolink AG, Gleichmann E. Diseases caused by reactions
of T lymphocytes towards incompatible structures of the major histocompatibility
complex. VI. Autoantibodies characteristic of systemic lupus erythematosus induced by
abnormal T-B cell cooperation across I-E. J Exp Med 1982;155:1555-60.
[19] Doutrelepont JM, Moser M, Leo O, Abramowicz D, Vanderhaegen ML, Urbain J, et al.
Hyper IgE in stimulatory graft-versus-host disease: role of interleukin-4. Clin Exp
Immunol 1991;83:133-6.
[20] Allen RD, Staley TA, Sidman CL. Differential cytokine expression in acute and chronic
murine graft-versus-host-disease. Eur J Immunol 1993;23:333-7.
[21] De Wit D, Van Mechelen M, Zanin C, Doutrelepont JM, Velu T, Gerard C, et al. Pref-
erential activation of Th2 cells in chronic graft-versus-host reaction. J Immunol
1993;150:361-6.
[22] Wynn TA, Cheever AW, Jankovic D, Poindexter RW, Caspar P, Lewis FA, et al. An IL-12-
based vaccination method for preventing fibrosis induced by schistosome infection.
Nature 1995;376:594-6.
[23] Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+
regulatory T cells in cancer patients. Blood 2006;107:2409-14.
[24] Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in
Foxp3-expressing regulatory T cells. Nat Immunol 2005;6:1142-51.
[25] Kawano Y, Kim HT, Matsuoka K, Bascug G, McDonough S, Ho VT, et al. Low telomerase
activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hemato-
poietic stem cell transplantation. Blood 2011;118:5021-30.
[26] Setoguchi R, Hori S, Takahashi T, Sakaguchi S. Homeostatic maintenance of natural
Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of auto-
immune disease by IL-2 neutralization. J Exp Med 2005;201:723-35.
[27] Zhang H, Chua KS, Guimond M, Kapoor V, Brown MV, Fleisher TA, et al. Lymphopenia
and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med
2005;11:1238-43.
[28] Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, Arumugarajah S, et al. Reduced frequency
of FOXP3+CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host
disease. Blood 2005;106:2903-11.
[29] Rozmus J, Schultz KR, Wynne K, Kariminia A, Satyanarayana P, Krailo M, et al. Early and
late extensive chronic graft-versus-host disease in children is characterized by different
Th1/Th2 cytokine profiles: findings of the Children's Oncology Group Study ASCT0031.
Biol Blood Marrow Transplant 2011;17:1804-13.
319
Search WWH ::
Custom Search